Seviteronel - Innocrin Pharmaceuticals

Drug Profile

Seviteronel - Innocrin Pharmaceuticals

Alternative Names: VT-464

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Innocrin Pharmaceuticals
  • Class Antiandrogens; Antineoplastics; Fluorine compounds; Naphthalenes; Propanols; Small molecules; Triazoles
  • Mechanism of Action Androgen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer

Most Recent Events

  • 03 Jul 2018 Innocrin Pharmaceuticals plans a phase II trial for Solid tumours (Late-stage disease, Androgen receptor positive) in Australia (ACTRN12618001074280)
  • 01 Nov 2017 Innocrin Pharmaceutical completes a phase II trial in Prostate cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT02130700)
  • 20 Jun 2017 The EMEA grants Small and Medium Enterprise (SME) status to Innocrin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top